BridgeBio Pharma ROA 2018-2026 | BBIO
Current and historical return on assets (ROA) values for BridgeBio Pharma (BBIO) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| BridgeBio Pharma ROA - Return on Assets Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Total Assets | Return on Assets |
| 2026-03-31 | $-0.72B | $1.10B | -65.86% |
| 2025-12-31 | $-0.73B | $0.97B | -74.44% |
| 2025-09-30 | $-0.80B | $0.97B | -82.19% |
| 2025-06-30 | $-0.78B | $0.89B | -87.54% |
| 2025-03-31 | $-0.67B | $0.82B | -81.84% |
| 2024-12-31 | $-0.54B | $0.81B | -66.32% |
| 2024-09-30 | $-0.44B | $0.71B | -61.39% |
| 2024-06-30 | $-0.45B | $0.71B | -63.71% |
| 2024-03-31 | $-0.54B | $0.64B | -84.26% |
| 2023-12-31 | $-0.64B | $0.58B | -110.34% |
| 2023-09-30 | $-0.61B | $0.60B | -101.83% |
| 2023-06-30 | $-0.57B | $0.62B | -92.34% |
| 2023-03-31 | $-0.43B | $0.71B | -59.86% |
| 2022-12-31 | $-0.48B | $0.76B | -63.56% |
| 2022-09-30 | $-0.49B | $0.85B | -57.36% |
| 2022-06-30 | $-0.51B | $0.87B | -58.67% |
| 2022-03-31 | $-0.60B | $0.92B | -64.52% |
| 2021-12-31 | $-0.56B | $0.99B | -56.64% |
| 2021-09-30 | $-0.54B | $0.92B | -58.47% |
| 2021-06-30 | $-0.50B | $0.92B | -54.01% |
| 2021-03-31 | $-0.52B | $0.87B | -59.60% |
| 2020-12-31 | $-0.45B | $0.85B | -53.03% |
| 2020-09-30 | $-0.40B | $0.83B | -48.51% |
| 2020-06-30 | $-0.35B | $0.79B | -43.69% |
| 2020-03-31 | $-0.29B | $0.57B | -51.44% |
| 2019-12-31 | $-0.26B | $0.32B | -81.70% |
| 2019-06-30 | $-0.16B | 0 | 0.00% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $14.460B | $0.502B |
| BridgeBio Pharma Inc. is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio Pharma Inc. is based in PALO ALTO, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |